UK: Novo Holdings and TA Associates team up to accelerate Biocomposites’ growth phase

Investment firm Novo Holdings from Denmark is making a strategic investment in Biocomposites, a UK-based medical devices company specializing in products for infection management in bone and soft tissue. The transaction involves the reinvestment of US private equity firm TA Associates, Biocomposites’ majority shareholder since 2017, alongside Novo Holdings and Biocomposites’ management. This partnership gives both TA and Novo Holdings equal control over the company’s operations.

Biocomposites, headquartered in Keele, produces calcium compounds and specialty polymer products used by surgeons globally in over 100 countries. With over 30 years of experience, their innovative solutions are utilized in more than a million procedures annually across various medical specialties such as musculoskeletal infections, orthopedics, trauma, spine, foot and ankle, and sports injuries. Since joining forces with TA in 2017, Biocomposites has seen a significant threefold increase in revenue, expanded its market reach, and broadened its product portfolio. The company has also completed two strategic acquisitions, enhancing its global presence and allowing entry into new indications and areas of therapy.

The new investment from Novo Holdings, combined with TA’s ongoing support, will propel Biocomposites to capitalize on its past achievements and drive further growth. The company aims to strengthen its worldwide presence and advance its innovative product pipeline to provide impactful solutions on a larger scale. Biocomposites’ CEO, Michael Harris, expressed confidence in the company’s accomplishments and future growth prospects, citing the investment as a significant validation of their success.

While specific financial details of the transaction were not disclosed, Jefferies acted as the exclusive financial advisor, and Goodwin Procter provided legal counsel for TA and Biocomposites. Legal advisors for Novo Holdings included Kirkland & Ellis International and Linklaters, while Alvarez & Marsal conducted financial and tax due diligence for Biocomposites. Squire Patton Boggs handled legal matters, KPMG oversaw tax-related aspects, and Jamieson Corporate Finance provided management advisory services for Biocomposites Management.

In conclusion, the partnership between Novo Holdings and TA Associates positions Biocomposites for a promising future of continued growth and innovation. With a strong track record of success and a commitment to advancing medical solutions, Biocomposites is well-positioned to make a significant impact in the healthcare industry through its groundbreaking products and global expansion efforts.